ClinConnect ClinConnect Logo
Search / Trial NCT03993418

Physiological Effects of Stevia Consumption in Humans

Launched by UNIVERSITY OF MANCHESTER · Jun 18, 2019

Trial Information

Current as of August 22, 2025

Completed

Keywords

ClinConnect Summary

Excess consumption of caloric sweeteners contributes to the alarming rates of overweight and obesity, whereas non-nutritive sweeteners (NNS) are non-caloric alternatives offering sensory and health benefits. NNS are widely used to moderate energy intake and postprandial glycaemia, but there is controversial evidence about their role and effects. Stevia, a natural NNS, has been suggested to assist with glucose regulation but data on glucose tolerance after daily consumption of stevia are lacking. The investigators plan to undertake a pilot randomized 2-parallel arm open-label 12-week trial, ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18-40 years
  • BMI 18.5-25 kg/m2
  • No or low NNS consumers (up to 1 can of diet soda per week or 1 sachet of NNS per week)
  • DEBQ for restraint eating ≤ 3
  • Healthy - general good health
  • Not taking medications that affect metabolism or appetite (i.e. thiazide diuretics, glucocorticoids or beta blockers)
  • Stable weight, ≤ 5 kg last 12 months
  • Fasting blood glucose ≤6.0 mmol/L
  • Willing to comply with the study protocol
  • No self-reported food allergy or intolerance to foods supplied during the study
  • The participant is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • The participant is able to read, comprehend and record information written in English.
  • A signed and dated written informed consent is obtained from the participant.
  • Exclusion Criteria:
  • Age under 18 years or over 40 years old.
  • BMI \>25 kg/m2 and \<18.5kg/m2
  • Participants who are not willing to comply with study procedures (including expression of dislike for NNS)
  • Habitual NNS consumers, \>1 can of diet beverage or \>1 sachet of low calorie sweeteners per week.
  • Fasting blood glucose measured \> 6 mmol/L
  • Subjects who are currently dieting and having ceased a diet in \< 4 weeks
  • DEBQ score for restraint eating \> 3
  • Subjects who follow special diets for weight maintenance, such as Atkins Diet, Weight Watchers, gluten-free diet, The Zone diet, Vegetarian Diet, Raw Food Diet etc.
  • Vegetarians, vegans
  • Subjects who take recreational substances such as cannabis.
  • Presence of any chronic condition requiring medication that might affect our results (e.g. diabetes, mental diseases, gastrointestinal diseases)
  • Subjects with eating disorders (binge eating disorder, bulimia etc)
  • Subjects who are currently experiencing anxiety or depression
  • Participants who drink alcohol more than the NHS guidelines (14 units per week)
  • \>10 h of vigorous physical activities per week and/or planning to increase/decrease physical activity levels in the next months.
  • Having ceased smoking in the last six months
  • Female participants who are, or may be, pregnant, or currently lactating.
  • Subjects who regularly consume dietary supplements for weight loss, muscle building etc.
  • Subjects with food allergies or intolerances related to the study.
  • Subjects who have given blood elsewhere within the last month.
  • The participant cannot read, comprehend and record information written in English.

About University Of Manchester

The University of Manchester is a leading research institution known for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university leverages its extensive expertise in biomedical research and clinical practice to develop and evaluate new therapies and interventions. The institution is dedicated to improving patient outcomes and public health by conducting rigorous, ethically sound trials that adhere to the highest standards of scientific integrity. Through its state-of-the-art facilities and a robust network of healthcare partnerships, the University of Manchester actively contributes to the global body of medical knowledge and the translation of research findings into clinical applications.

Locations

Manchester, , United Kingdom

Patients applied

0 patients applied

Trial Officials

John McLaughlin

Principal Investigator

University of Manchester

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials